However, different SGLT2 inhibitors have different off-target effects (Mancini et al., 2018; Behnammanesh et al., 2020), meaning that even though empagliflozin has protective effects on PAH, other SGLT2 inhibitors may not. Here, SLC5A2 is linked to pulmonary arterial hypertension.